L Vitek, C Bellarosa, C Tiribelli - Clinical Pharmacology & …, 2019 - Wiley Online Library
Observational epidemiological studies showed that mild hyperbilirubinemia has beneficial effects on the prevention of cardiovascular disease, type 2 diabetes mellitus, and metabolic …
HMG-CoA reductase inhibitors (statins) are the mainstay in the pharmacologic management of dyslipidemia. Since they are widely prescribed, their safety remains an issue of concern …
TT Li, JX An, JY Xu, BG Tuo - World Journal of Clinical Cases, 2019 - ncbi.nlm.nih.gov
Organic anion transporters (OATs) and organic anion transporter polypeptides (OATPs) are classified within two SLC superfamilies, namely, the SLC22A superfamily and the SLCO …
L Vítek, C Tiribelli - Journal of Hepatology, 2023 - Elsevier
Gilbert´ s syndrome, also known as benign hyperbilirubinemia, was described more than 100 years ago. It has usually been considered a physiological abnormality characterized by …
M Murray, F Zhou - British journal of pharmacology, 2017 - Wiley Online Library
Organic anion transporters (OATs) and organic anion‐transporting polypeptides (OATPs), encoded by a number of solute carrier (SLC) 22A and SLC organic anion (SLCO) genes …
S Zhou, Y Shu - Drug Metabolism and Disposition, 2022 - ASPET
Facilitated transport is necessitated for large size, charged, and/or hydrophilic drugs to move across the membrane. The drug transporters in the solute carrier (SLC) superfamily, mainly …
T Ruutu, E Juvonen, M Remberger, K Remes… - Biology of Blood and …, 2014 - Elsevier
We report the long-term results of a prospective randomized study on the use of ursodeoxycholic acid (UDCA) for prevention of hepatic complications after allogeneic stem …
HA Barton, Y Lai, TC Goosen, HM Jones… - Expert opinion on …, 2013 - Taylor & Francis
Introduction: Membrane transporters have been recognized to play a key role in determining the absorption, distribution and elimination processes of drugs. The organic anion …
M Hu, B Tomlinson - Expert opinion on drug metabolism & …, 2014 - Taylor & Francis
Introduction: Statins are the cornerstone of lipid-lowering therapy to reduce the risk of coronary heart disease. Rosuvastatin and pitavastatin are the two recently developed statins …